CXCR
| 货号 | 产品名 | CAS号 | 信息 |
|---|---|---|---|
| FB09422 | ZK756326 | 874911-96-3 | ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1. |
| FB08826 | WZ811 | 55778-02-4 | WZ811 is a small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM. |
| FB12740 | VUF 11222 | 1414376-84-3 | VUF-11222 is a high affinity non-peptide CXCR3 agonist (pKi = 7.2). |
| FB15218 | USL-311 | 1373268-67-7 | USL311 is a selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1]. |
| FB07161 | UNBS5162 | 956590-23-1 | UNBS5162 is a naphthalimide and a hydrolysis product of UNBS3157 that decreases CXCL chemokine expression in experimental prostate cancers and the mean antiproliferative activity IC50 value is 17.9 μM for 9 cancer cell lines. |
| FB19653 | Tannic Acid | 1401-55-4 | Tannic acid is a novel hERG channel blocker with IC50 of 3.4 μM. |
| FB17960 | SX-682 | 1648843-04-2 | SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity. |
| FB02350 | SRT3190 | 1204707-73-2 | SRT3190 is CXCR2 ligand. |
| FB02349 | SRT3109 | 1204707-71-0 | SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions. |
| FB09094 | SCH-563705 | 473728-58-4 | SCH-563705 is a potent dual CXCR2 (IC50= 1.3 nM)/CXCR1 (IC50= 7.3 nM) antagonist. |
| FB07027 | SCH-527123 | 473727-83-2 | SCH-527123 is a potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively. |
| FB03068 | SCH-546738 | 906805-42-3 | SCH 546738 is a potent and non-competitive small molecule CXCR3 antagonist with Ki of 0.4 nM . |
| FB01402 | SB-225002 | 182498-32-4 | SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM, showing > 150-fold selectivity over CXCR1 and four other 7-TMRs. |
| FB12676 | SB 332235 | 276702-15-9 | SB-332235 is a potent and specific CXCR2 antagonist. SB-332235 effectively inhibited CS-induced neutrophilia in a dose-dependent manner. |
| FB12433 | SB 265610 | 211096-49-0 | SB-265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo. |
| FB04852 | Reparixin L-lysine | 266359-93-7 | Reparixin L-lysine is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation,which has been shown to attenuate inflammatory responses in various injury models. |
| FB08780 | Reparixin | 266359-83-5 | Reparixin is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation, which has been shown to attenuate inflammatory responses in various injury models. |
| FB01744 | Plerixafor | 110078-46-1 | Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
| FB04612 | Plerixafor 8HCl | 155148-31-5 | Plerixafor 8HCl is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively. |
| FB12483 | NVP CXCR2 20 | 1029521-30-9 | NVP CXCR2 20 is a potent and selective CXCR2 antagonist with IC50 of 40 nM. |
| FB06848 | NBI-74330 | 855527-92-3 | NBI-74330 is a small molecule antagonist for CXCR3, NBI-74330 demonstrates potent inhibition of [(125)I]CXCL10 and [(125)I]CXCL11 specific binding (K (i) of 1.5 and 3.2 nM, respectively. |
| FB11664 | MSX-130 | 4051-59-6 | MSX-130 is CXCR4 Antagonist. |
| FB06912 | MSX-122 | 897657-95-3 | MSX-122 is a small molecule and partial CXCR4 antagonist, with potent inhibition of CXCR4/CXCL12 actions (IC50 = 10 nM). |
| FB11596 | LY2510924 | 1088715-84-7 | LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity. Upon subcutaneous administration, LY2510924 binds to the chemokine receptor CXCR4, thereby preventing CXCR4 binding to its ligand, stromal derived factor-1 (SDF-1), and subsequent receptor activation. |
| FB12354 | LIT-927 | 2172879-52-4 | LIT-927 is a neutraligand of CXCL12 (Ki= 267 nM) with anti-inflammatory effect and it has a high binding selectivity for CXCL12 over other chemokines |
| FB15795 | JMS-17-2 | 1380392-05-1 | JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. |
| FB12234 | IT1t 2HCl | 1092776-63-0 | IT1t 2HCl is a potent CXCR4 antagonist with IC50 of 1.1 nM. |
| FB12205 | FC 131 | 606968-52-9 | FC 131 is a CXCR4 antagonist with IC50 of 126 nM. |
| FB07158 | Danirixin | 954126-98-8 | Danirixin is a small molecule, non-peptide, high affinity (IC50 for CXCL8 binding = 12.5 nM), selective, and reversible CXCR2 antagonist. |
| FB12683 | TC 14012 | 368874-34-4 | CXCR4 antagonist; ACKR3 (CXCR7) agonist |
| FB12177 | CTCE 9908 | 1030384-98-5 | CTCE 9908 is a CXCR4 antagonist with antitumor activity. |
| FB10304 | BKT140 | 664334-36-5 | BKT140 is a CXCR4 antagonist with an IC50 value of ~1 nM. |
| FB12358 | AZD5069 | 878385-84-3 | AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 9.1. |
| FB12242 | AZ 10397767 | 333742-63-5 | AZ 10397767 is a potent CXCR2 antagonist with IC50 of 1 nM. |
| FB10231 | ATI-2341 | 1337878-62-2 | ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. |
| FB06147 | AMG-487 | 473719-41-4 | AMG-487 is a small molecule antagonist of the chemokine receptor CXCR3 and inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3. |
| FB03055 | AMD-070 | 558447-26-0 | AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
| FB15756 | Mavorixafor 3HCl | 2309699-17-8 | AMD-070 is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
| FB00765 | AMD-070 HCl | 880549-30-4 | AMD-070 HCl is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs. |
| FB04028 | AMD 3465 | 185991-24-6 | AMD 3465 is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM). |
| FB03356 | AMD 3465 Hexahydrobromide | 185991-07-5 | AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM). |
| FB12176 | (±)-NBI 74330 | 473722-68-8 | (±)-NBI 74330 is a potent and selective CXCR3 antagonist that potently inhibits 125I-CXCL10 binding to CXCR3 with pKi of 8.13. |
| FB12238 | (±)-AMG 487 | 947536-03-0 | (±)-AMG 487 is an antagonist of CXCR3 that inhibits binding of 125I-IP-10 and 125I-ITAC to CXCR3 with IC50 of 8.0 and 8.2 nM respectively. |